Q: For the purposes of determining a Medicare overpayment, should claims that we are uncertain whether they were appropriate be included? Is this defined under the False Claims Act (FCA)?
Q: CMS created a new MS-DRG for chimeric antigen receptor T-cell (CAR-T) therapies in the fiscal year (FY) 2021 IPPS final rule. Which ICD-10-PCS codes group to this new MS-DRG and does it qualify for an additional new technology add-on payment?
Q: Workers will likely remain remote for the foreseeable future, but as coffee shops and restaurants begin to reopen, it’s possible that employees may be accessing protected health information (PH) in these locations. While it is best practice to avoid doing this altogether, what should employees do to avoid exposing PHI in this scenario?
Q: CMS recently updated its Care Compare tool, a resource that can provide valuable insight for any patient. How can case managers ensure that their patents can access and best utilize this tool?
Q: If employees are working remotely and accessing protected health information (PHI) not only on their computers and mobile devices, but printing it as well, how should they safely dispose of the printed PHI?
Our coding experts answer questions about reporting modifier -58 for physicians and facilities, developing a charge capture audit process, and interpreting the 2021 E/M guidelines.
Q: Starting January 1, 2021, CMS will be lowering reimbursement for high throughput novel coronavirus (COVID-19) diagnostic tests from $100 to $75. I understand that if certain requirements are met labs will be eligible to bill for a $25 add on code. How can we meet the requirements for the add on code?
